<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00732056</url>
  </required_header>
  <id_info>
    <org_study_id>GRN163L CP14A010</org_study_id>
    <nct_id>NCT00732056</nct_id>
  </id_info>
  <brief_title>A Study of GRN163L With Paclitaxel and Bevacizumab to Treat Patients With Locally Recurrent Or Metastatic Breast Cancer</brief_title>
  <official_title>A Phase I/II Study of GRN163L in Combination With Paclitaxel and Bevacizumab in Patients With Locally Recurrent or Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Geron Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Geron Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the maximum tolerated dose (MTD) of GRN163L in&#xD;
      combination with paclitaxel and bevacizumab in patients with locally recurrent or metastatic&#xD;
      breast cancer (MBC)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      GRN163L is a telomerase template antagonist with in vitro and in vivo activity in a variety&#xD;
      of tumor model systems. Telomerase is an enzyme that is active primarily in tumor cells and&#xD;
      is crucial for the indefinite growth of tumor cells. Inhibition of telomerase may result in&#xD;
      antineoplastic effects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety, MTD, efficacy</measure>
    <time_frame>First 4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK and efficacy</measure>
    <time_frame>Baseline to end of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3+3 cohort dose escalation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GRN163L</intervention_name>
    <description>25% dose escalation infused over 2 hours weekly</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed adenocarcinoma of the breast with measurable&#xD;
             locally recurrent or metastatic disease&#xD;
&#xD;
          -  May have had one prior non-taxane chemotherapy regimen for metastatic disease&#xD;
&#xD;
          -  If HER2 positive, must have had prior treatment with trastuzumab (Herceptin®)&#xD;
&#xD;
          -  If previously treated with an anthracycline, anthracenedione, or trastuzumab must be&#xD;
             tested by MUGA scan or echocardiogram and have LVEF ≥ 50%&#xD;
&#xD;
          -  Must have recovered from most recent radiation treatment or surgical procedure&#xD;
&#xD;
          -  ECOG performance status of 0 or 1&#xD;
&#xD;
          -  Life expectancy ≥ 3 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Locally recurrent disease amenable to resection with curative intent&#xD;
&#xD;
          -  Prior adjuvant or neoadjuvant taxane chemotherapy within 12 months prior to first&#xD;
             study drug administration&#xD;
&#xD;
          -  Investigational therapy within 4 weeks prior to first study drug administration&#xD;
&#xD;
          -  Prior hormonal therapy within 2 weeks prior to first study drug administration&#xD;
&#xD;
          -  Prior radiotherapy within 2 weeks prior to first study drug administration&#xD;
&#xD;
          -  Cytotoxic chemotherapy within 2 weeks prior to first study drug administration&#xD;
&#xD;
          -  Therapeutic anticoagulation or regular use of anti-platelet therapy within 2 weeks&#xD;
             prior to first study drug administration NOTE: Low-dose anticoagulant therapy to&#xD;
             maintain patency of a vascular access device is allowed.&#xD;
&#xD;
          -  Prolongation of PT or INR, aPTT &gt; ULN, or fibrinogen &lt; LLN&#xD;
&#xD;
          -  Active or chronically current bleeding (eg, active peptic ulcer)&#xD;
&#xD;
          -  Clinically significant cardiovascular or cerebrovascular disease including&#xD;
&#xD;
        Any history of:&#xD;
&#xD;
          -  Cerebrovascular disease including TIA, stroke or subarachnoid hemorrhage&#xD;
&#xD;
          -  Ischemic bowel&#xD;
&#xD;
        Within the last 12 months:&#xD;
&#xD;
          -  MI&#xD;
&#xD;
          -  Unstable angina&#xD;
&#xD;
          -  NYHA grade II or greater CHF&#xD;
&#xD;
          -  Grade 2 or greater peripheral vascular disease&#xD;
&#xD;
        Active at study entry:&#xD;
&#xD;
          -  Uncontrolled hypertension defined as SBP &gt; 160 or DBP &gt; 90&#xD;
&#xD;
          -  Uncontrolled or clinically significant arrhythmia&#xD;
&#xD;
          -  Clinically relevant active infection&#xD;
&#xD;
          -  Nonhealing wound or fracture&#xD;
&#xD;
          -  Serious co-morbid medical conditions, including cirrhosis and chronic obstructive or&#xD;
             chronic restrictive pulmonary disease&#xD;
&#xD;
          -  Active autoimmune disease requiring immunosuppressive therapy&#xD;
&#xD;
          -  Known positive serology for HIV&#xD;
&#xD;
          -  Prior malignancy (within the last 3 years) except for adequately treated basal cell or&#xD;
             squamous cell skin cancer, in situ cervical cancer, in situ breast cancer, or in situ&#xD;
             prostate cancer, or other cancer for which the patient has been disease-free for at&#xD;
             least 3 years&#xD;
&#xD;
          -  Any other severe, acute, or chronic medical or psychiatric condition, laboratory&#xD;
             abnormality, or difficult complying with protocol requirements that may increase the&#xD;
             risk associated with study participation or study drug administration or may interfere&#xD;
             with the interpretation of study results and, in the judgment of the investigator,&#xD;
             would make the patient inappropriate for this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathy Miller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University Melvin and Bren Simon Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ingalls Memorial Hospital</name>
      <address>
        <city>Harvey</city>
        <state>Illinois</state>
        <zip>60426</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Melvin and Bren Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.geron.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>December 2015</verification_date>
  <study_first_submitted>August 7, 2008</study_first_submitted>
  <study_first_submitted_qc>August 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2008</study_first_posted>
  <last_update_submitted>December 22, 2015</last_update_submitted>
  <last_update_submitted_qc>December 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic Breast Cancer</keyword>
  <keyword>Recurrent Breast Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

